Vitamin K nutrition, metabolism, and requirements: Current concepts and future research

Advances in Nutrition

Volumn 3, Issue 2, 2012, Pages 182-195

  Shearer, Martin J ^a   Fu, Xueyan ^b   Booth, Sarah L ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNOQUINONE; PHYTOMENADIONE; VITAMIN K GROUP;

ADULT; BIOAVAILABILITY; BONE; FEMALE; HUMAN; INFANT; INTESTINE ABSORPTION; LIVER; MALE; METABOLISM; NEWBORN; NUTRITIONAL REQUIREMENT; REVIEW;

ADULT; BIOLOGICAL AVAILABILITY; BONE AND BONES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTESTINAL ABSORPTION; LIVER; MALE; NUTRITIONAL REQUIREMENTS; VITAMIN K; VITAMIN K 1; VITAMIN K 2;

EID: 84866283031     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.111.001800     Document Type: Review

References (110)

1. Food and Nutrition Board. Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC:National Academies Press; 2001.
2. Ji Y, Li X, Tso P. Intestinal fatty acid absorption. Immununol Endocr Metab Agents Med Chem. 2009;9:60-73.
3. Holst B, Williamson G. Nutrients and phytochemicals:from bioavailability to bioefficacy beyond antioxidants. Curr Opin Biotechnol. 2008;19:73-82.
4. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr. 1998;128:785-8.
5. Gijsbers BL, Jie KS, Vermeer C. Effect of food composition on vitamin K absorption in human volunteers. Br J Nutr. 1996;76:223-9.
6. Garber AK, Binkley NC, Krueger DC, Suttie JW. Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. J Nutr. 1999;129:1201-3.
7. Booth SL, Lichtenstein AH, Dallal GE. Phylloquinone absorption from phylloquinone-fortified oil is greater than from a vegetable in younger and older men and women. J Nutr. 2002;132:2609-12.
8. Dolnikowski GG, Sun Z, Grusak MA, Peterson JW, Booth SL. HPLC and GC/MS determination of deuterated vitamin K (phylloquinone) in human serum after ingestion of deuterium-labeled broccoli. J Nutr Biochem. 2002;13:168-74.
9. Erkkilä AT, Lichtenstein AH, Dolnikowski GG, Grusak MA, Jalbert SM, Aquino KA, Peterson JW, Booth SL. Plasma transport of vitamin K in men using deuterium-labeled collard greens.Metabolism. 2004;53:215-21.
10. Fu X, Peterson JW, Hdeib M, Booth SL, Grusak MA, Lichtenstein AH, Dolnikowski GG. Measurement of deuterium-labeled phylloquinone in plasma by high-performance liquid chromatography/mass spectrometry. Anal Chem. 2009;81:5421-5.
11. Jones KS, Bluck LJ, Wang LY, Coward WA. A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. Eur J Clin Nutr. 2008;62:1273-81.
12. Jones KS, Bluck LJ, Wang LY, Stephen AM, Prynne CJ, Coward WA. The effect of different meals on the absorption of stable isotopelabelled phylloquinone. Br J Nutr. 2009;102:1195-202.
13. Kurilich AC, Britz SJ, Clevidence BA, Novotny JA. Isotopic labeling and LC-APCI-MS quantification for investigating absorption of carotenoids and phylloquinone from kale (Brassica oleracea). J Agric Food Chem. 2003;51:4877-83.
14. Novotny JA, Kurilich AC, Britz SJ, Baer DJ, Clevidence BA. Vitamin K absorption and kinetics in human subjects after consumption of 13Clabelled phylloquinone from kale. Br J Nutr. 2010;104:858-62.
15. Shearer MJ, McBurney A, Barkhan P. Studies on the absorption and metabolism of phylloquinone (vitamin K1) in man. Vitam Horm. 1974;32:513-42.
16. Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta. 2002;1570:27-32.
17. Shearer MJ. Vitamin K metabolism and nutriture. Blood Rev. 1992;6:92-104.
18. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 1995;15:399-417.
19. Blomstrand R, Forsgren L. Vitamin K1-3H in man. Its intestinal absorption and transport in the thoracic duct lymph. Int Z Vitaminforsch. 1968;38:45-64.
20. Shearer MJ, Barkhan P, Webster GR. Absorption and excretion of an oral dose of tritiated vitamin K1 in man. Br J Haematol. 1970;18:297-308.
21. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr. 1998;67:1226-31.
22. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans:a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism. 1990;39:357-65.
23. Meydani M, Cohn JS, Macauley JB, McNamara JR, Blumberg JB, Schaefer EJ. Postprandial changes in the plasma concentration of alpha-and gamma-tocopherol in human subjects fed a fat-rich meal supplemented with fat-soluble vitamins. J Nutr. 1989;119:1252-8.
24. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997;38:2173-92.
25. Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1060-7.
26. Ji ZS, Fazio S, Lee YL, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem. 1994;269:2764-72.
27. Shimano H, Namba Y, Ohsuga J, Kawamura M, Yamamoto K, Shimada M, Gotoda T, Harada K, Yazaki Y, Yamada N. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest. 1994;93:2215.
28. Mahley RW, Hussain MM. Chylomicron and chylomicron remnant catabolism. Curr Opin Lipidol. 1991;2:170.
29. Shearer MJ, Barkhan P. Studies on the metabolites of phylloquinone (vitamin K 1) in the urine of man. Biochim Biophys Acta. 1973;297:300-12.
30. Shearer MJ, Mallinson CN, Webster GR, Barkhan P. Clearance from plasma and excretion in urine, faeces and bile of an intravenous dose of tritiated vitamin K 1 in man. Br J Haematol. 1972;22:579-88.
31. Booth SL. Roles for vitamin K beyond coagulation. Annu Rev Nutr. 2009;29:89-110.
32. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, Brandenburg VM, Bekers O, Vermeer C. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010;104:811-22.
33. Newman P, Bonello F, Wierzbicki AS, Lumb P, Savidge GF, Shearer MJ. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells:role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res. 2002;17:426-33.
34. Booth SL, O'Brien-Morse ME, Dallal GE, Davidson KW, Gundberg CM. Response of vitamin K status to different intakes and sources of phylloquinone-rich foods:comparison of younger and older adults. Am J Clin Nutr. 1999;70:368-77.
35. Niemeier A, Kassem M, Toedter K, Wendt D, Ruether W, Beisiegel U, Heeren J. Expression of LRP1 by human osteoblasts:a mechanism for the delivery of lipoproteins and vitamin K1 to bone. J Bone Miner Res. 2005;20:283-93.
36. Hussain MM, Goldberg IJ, Weisgraber KH, Mahley RW, Innerarity TL. Uptake of chylomicrons by the liver, but not by the bone marrow, is modulated by lipoprotein lipase activity. Arterioscler Thromb Vasc Biol. 1997;17:1407-13.
37. Hussain MM, Mahley RW, Boyles JK, Fainaru M, Brecht WJ, Lindquist PA. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. J Biol Chem. 1989;264:9571-82.
38. Hussain MM, Mahley RW, Boyles JK, Lindquist PA, Brecht WJ, Innerarity TL. Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. J Biol Chem. 1989;264:17931-8.
39. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J Nutr. 1996;126:S1192-6.
40. Niemeier A, Niedzielska D, Secer R, Schilling A, Merkel M, Enrich C, Rensen PC, Heeren J. Uptake of postprandial lipoproteins into bone in vivo:impact on osteoblast function. Bone. 2008;43:230-7.
41. Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, Vermeer C. Vitamin K-containing dietary supplements:comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109:3279-83.
42. Booth SL, Tucker KL, McKeown NM, Davidson KW, Dallal GE, Sadowski JA. Relationships between dietary intakes and fasting plasma concentrations of fat-soluble vitamins in humans. J Nutr. 1997;127:587-92.
43. Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, D'Agostino RB Sr, Ordovas JM, O'Donnell CJ, Dawson-Hughes B, Vasan RS, et al. Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr. 2009;63:458-64.
44. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest. 1987;80:1571-7.
45. Boerwinkle E, Brown S, Sharrett AR, Heiss G, Patsch W. Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am J Hum Genet. 1994;54:341-60.
46. Cortner JA, Coates PM, Le NA, Cryer DR, Ragni MC, Faulkner A, Langer T. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J Lipid Res. 1987;28:195-206.
47. Saupe J, Shearer MJ, Kohlmeier M. Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr. 1993;58:204-8.
48. Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, Miller LM, Koschinsky ML, Booth SL. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis. 2007;49:432-9.
49. Yan L, Zhou B, Nigdikar S, Wang X, Bennett J, Prentice A. Effect of apolipoprotein E genotype on vitamin K status in healthy older adults from China and the UK. Br J Nutr. 2005;94:956-61.
50. Crosier M, Shea MK, Ordovas JM, Gundberg CM, Dawson-Hughes B, Booth SL. Apolipoprotein E genotype is a determinant of serum vitamin K, but not BMD, in older men and women. J Bone Miner Res. 2005;20:S343.
51. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest. 1981;68:1075-85.
52. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteinearginine interchange at a single site. J Biol Chem. 1982;257:2518-21.
53. Bergeron N, Havel RJ. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele. J Clin Invest. 1996;97:65-72.
54. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8:53-60.
55. Kohnke H, Sorlin K, Granath G,Wadelius M.Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol. 2005;61:381-8.
56. Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics. 2005;15:69-74.
57. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics. 2006;16:609-11.
58. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, Ali SS, Mohamed ME, Langaee T, Johnson JA. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011;21:130-5.
59. Sokoll LJ, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr. 1996;63:566-73.
60. Nakagawa K, Hirota Y, Sawada N, Yuge N, Watanabe M, Uchino Y, Okuda N, Shimomura Y, Suhara Y, Okano T. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 2010; 468:117-21.
61. Thijssen HH, Vervoort LM, Schurgers LJ, Shearer MJ. Menadione is a metabolite of oral vitamin K. Br J Nutr. 2006;95:260-6.
62. Oldenburg J, Marinova M, Muller-Reible C, Watzka M. The vitamin K cycle. Vitam Horm. 2008;78:35-62.
63. Tie JK, Stafford DW. Structure and function of vitamin K epoxide reductase. Vitam Horm. 2008;78:103-30.
64. Wu S, Liu S, Davis CH, Stafford DW, Kulman JD, Pedersen LG. A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle. J Theor Biol. 2011;279:143-9.
65. Oldenburg J, von Brederlow B, Fregin A, Rost S, Wolz W, Eberl W, Eber S, Lenz E, Schwaab R, Brackmann HH, et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductasecomplex. Thromb Haemost. 2000;84:937-41.
66. Goodstadt L, Ponting CP. Vitamin K epoxide reductase:homology, active site and catalytic mechanism. Trends Biochem Sci. 2004;29:289-92.
67. Rettie AE, Tai G. The pharmocogenomics of warfarin:closing in on personalized medicine. Mol Interv. 2006;6:223.
68. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gammaglutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-5.
69. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006;95:205-11.
70. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-70.
71. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation. 2006;113:1615-21.
72. Kinoshita H, Nakagawa K, Narusawa K, Goseki-Sone M, Fukushi-Irie M, Mizoi L, Yoshida H, Okano T, Nakamura T, Suzuki T, et al. A functional single nucleotide polymorphism in the vitamin-K-dependent gamma-glutamyl carboxylase gene (Arg325Gln) is associated with bone mineral density in elderly Japanese women. Bone. 2007;40:451-6.
73. Crosier MD, Peter I, Booth SL, Bennett G, Dawson-Hughes B, Ordovas JM. Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status. J Nutr Sci Vitaminol (Tokyo). 2009; 55:112-9.
74. Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011;305:1348-9.
75. McBurney A, Shearer MJ, Barkhan P. Preparative isolation and characterization of the urinary aglycones of vitamin K1 (phylloquinone in man. Biochem Med. 1980;24:250-67.
76. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008;100:530-47.
77. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-12.
78. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase:an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75:1337-46.
79. Harrington DJ, Booth SL, Card DJ, Shearer MJ. Excretion of the urinary 5C-and 7C-aglycone metabolites of vitamin K by young adults responds to changes in dietary phylloquinone and dihydrophylloquinone intakes. J Nutr. 2007;137:1763-8.
80. Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev. 2009;23:49-59.
81. Howe AM, Webster WS, Lipson AH, Halliday JL, Sheffield LJ. Binder's syndrome due to prenatal vitamin K deficiency:a theory of pathogenesis. Aust Dent J. 1992;37:453-60.
82. Irving MD, Chitty LS, Mansour S, Hall CM. Chondrodysplasia punctata:a clinical diagnostic and radiological review. Clin Dysmorphol. 2008;17:229-41.
83. Greer FR, Marshall S, Cherry J, Suttie JW. Vitamin K status of lactating mothers, human milk, and breast-feeding infants. Pediatrics. 1991;88:751-6.
84. Canfield LM, Hopkinson JM, Lima AF, Martin GS, Sugimoto K, Burr J, Clark L, McGee DL. Quantitation of vitamin K in human milk. Lipids. 1990;25:406-11.
85. Canfield LM, Hopkinson JM, Lima AF, Silva B, Garza C. Vitamin K in colostrum and mature human milk over the lactation period-a crosssectional study. Am J Clin Nutr. 1991;53:730-5.
86. von Kries R, Shearer M, McCarthy PT, Haug M, Harzer G, Gobel U. Vitamin K1 content of maternal milk:influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr Res. 1987;22:513-7.
87. Chuansumrit A, Plueksacheeva T, Hanpinitsak S, Sangwarn S, Chatvutinun S, Suthutvoravut U, Herabutya Y, Shearer MJ. Prevalence of subclinical vitamin K deficiency in Thai newborns:relationship to maternal phylloquinone intakes and delivery risk. Arch Dis Child Fetal Neonatal Ed. 2010;95:F104-8.
88. Shearer MJ, McCarthy PT, Crampton OE, Mattock MB. The assessment of human vitamin K status from tissue measurements. In:Suttie JW, editor. Current advances in vitamin K research. New York:Elsevier; 1988. p. 437-52.
89. American Association of Pediatrics. Report of Committee on Nutrition. Vitamin K compounds and the water-soluble analogues. Pediatrics. 1961;28:501-7.
90. Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. BMJ. 1992;305:341-6.
91. WHO. Priority medicines for mothers and children. Geneva:WHO; 2011.
92. Loughnan PM, McDougall PN. Does intramuscular vitamin K1 act as an unintended depot preparation? J Paediatr Child Health. 1996;32:251-4.
93. Tulchinsky TH, Patton MM, Randolph LA, Meyer MR, Linden JV. Mandating vitamin K prophylaxis for newborns in New York State. Am J Public Health. 1993;83:1166-8.
94. Busfield A, McNinch A, Tripp J. Neonatal vitamin K prophylaxis in Great Britain and Ireland:the impact of perceived risk and product licensing on effectiveness. Arch Dis Child. 2007;92:754-8.
95. Strehle EM, Howey C, Jones R. Evaluation of the acceptability of a new oral vitamin K prophylaxis for breastfed infants. Acta Paediatr. 2010;99:379-83.
96. Clarke P. Vitamin K prophylaxis for preterm infants. Early Hum Dev. 2010;86 Suppl 1:17-20.
97. Harrington DJ, Clarke P, Card DJ, Mitchell SJ, Shearer MJ. Urinary excretion of vitamin K metabolites in term and preterm infants:relationship to vitamin K status and prophylaxis. Pediatr Res. 2010;68:508-12.
98. Booth SL, Al Rajabi A. Determinants of vitamin K status in humans. Vitam Horm. 2008;78:1-22.
99. Frick PG, Riedler G, Brogli H. Dose response and minimal daily requirement for vitamin K in man. J Appl Physiol. 1967;23:387-9.
100. Erkkilä AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, Stampfer MJ, Lichtenstein AH. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr. 2005;59:196-204.
101. Booth SL, Broe K, Gagnon D, Tucker K, Hannan M, McLean R, Dawson-Hughes B, Wilson P, Cupples L, Kiel D. Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr. 2003;77:512-6.
102. Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson-Hughes B, Gundberg CM, Cupples LA, Wilson PW, Kiel DP. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 2004;89:4904-9.
103. Denisova NA, Booth SL. Vitamin K and sphingolipid metabolism:evidence to date. Nutr Rev. 2005;63:111-21.
104. Li J, Lin JC, Wang H, Peterson JW, Furie BC, Furie B, Booth SL, Volpe JJ, Rosenberg PA. Novel role of vitamin K in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci. 2003;23:5816-26.
105. Booth SL, Lichtenstein AH, O'Brien-Morse M, McKeown NM,Wood RJ, Saltzman E, Gundberg CM. Effects of a hydrogenated form of vitamin K on bone formation and resorption. Am J Clin Nutr. 2001;74:783-90.
106. Booth SL, Martini L, Peterson JW, Saltzman E, Dallal GE, Wood RJ. Dietary phylloquinone depletion and repletion in older women. J Nutr. 2003;133:2565-9.
107. Visser DY, Jansen NJ, Ijland MM, de Koning TJ, van Hasselt PM. Intracranial bleeding due to vitamin K deficiency:advantages of using a pediatric intensive care registry. Intensive CareMed. 2011;37:1014-20.
108. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93.
109. European Micronutrient Recommendations Aligned (Eurreca) Micronutrient Database. Nutri-RecQuest. http://www.serbianfood.info/eurreca/ Last accessed:February 2, 2012.
110. Kamao M, Suhara Y, Tsugawa N, Uwano M, Yamaguchi N, Uenishi K, Ishida H, Sasaki S, Okano T. Vitamin K content of foods and dietary vitamin K intake in Japanese young women. J Nutr Sci Vitaminol (Tokyo). 2007;53:464-70.